implicity
ILR ECG Analyzer · FDA-cleared · Class II

ILR ECG Analyzer†: fewer false-positive alerts to review from implantable loop recorders, across major manufacturers.

A second layer of AI review on top of your devices’ own filters. Up to 76% fewer false-positive episodes with high sensitivity1, so your team can spend more of its time on the patients who need it.

The residual-alert problem

Device AI got us part way there, but not all the way.

In an expert-adjudicated analysis of more than 2,600 ICM episodes across four manufacturers, a large share of what reached clinicians still wasn’t actionable, even on the newest AI-equipped devices.3

AI-equipped ICMs
32.9%

of transmitted episodes were non-actionable, even after the manufacturer’s own AI filtering.3

Non-AI ICMs
45.4%

of transmitted episodes were non-actionable on devices without on-board AI filtering.3

Pause episodes
46.8%

of pause alerts were false positives caused by R-wave undersensing: the heart kept beating, the device just missed it.3

Better device filters shrink the pile. A second, independent layer catches more of what’s left.

How it works

A second layer, built for what gets through.

The ILR ECG Analyzer† doesn’t replace your devices’ filtering. It picks up where it stops, reviewing the residual episodes that would otherwise land in your queue.

  1. 01
    Your ICMs transmitEpisodes arrive from Abbott, Biotronik, Boston Scientific and Medtronic loop recorders.
  2. 02
    Manufacturer filters run firstIn-device or cloud filtering removes the most obvious noise. Many false positives still get through.
  3. 03
    Implicity reviews what’s leftOur FDA-cleared algorithm analyzes each residual ECG and suggests which episodes are likely false positives.
  4. 04
    Your team makes the callSuggestions appear in the Implicity platform for clinician review. Accept or change them; the decision stays yours.

Illustrative animation of the review flow; proportions are not study data.

Inside the workflow

A second read on every episode, in the place you already work.

Each residual episode comes with an Implicity suggestion next to the device’s own label. Try a few examples to see what that looks like for your team.

  • One review standard for every brand. The same logic applies to every manufacturer’s loop recorders, so your clinic isn’t juggling five different definitions of a “pause.”
  • Real events stay in front of you. The algorithm is built for high sensitivity, so it’s designed to clear noise without hiding the episodes that need you.
  • No new hardware, no new portal. It runs inside the Implicity platform on the transmissions you already receive.
ICM · MedtronicTransmission · 06:42
Device labelPause≥3 s without detected beats
Implicity suggestionAnalyzing… 

Illustrative examples. Not actual patient data or algorithm output; every episode is reviewed by your clinical team.

Clinical evidence

Up to76%

fewer false-positive ICM episodes, on top of manufacturer filtering, while maintaining high sensitivity.1

EP Europace · 2026Performance of a cloud-based AI solution for reducing false-positive ICM alertsMulticenter evaluation presented at EHRA 2026, led by Varma, Wadhwa and colleagues.1
Heart Rhythm · 2026Reducing false positives on top of manufacturer AI algorithmsPresented at HRS 2026 by Marijon and colleagues, focused on the newest AI-equipped loop recorders.2
FDA 510(k) · July 2026Next-generation algorithm cleared as a Class II medical deviceCleared for ICM ECG data from major manufacturers and available now to U.S. customers.†

Manufacturer-agnostic

Major ICMs.
One intelligent review.

Most clinics follow loop recorders from more than one manufacturer, each with its own filtering and its own labels. The ILR ECG Analyzer† applies one consistent second-layer review across these manufacturers.

Abbott
Biotronik
Boston Scientific
Medtronic

Why we built it

AI should make expert cardiac care scalable without making it impersonal. Fewer false positives isn’t the win by itself, it’s what that time gets reinvested in. A quicker call to a decompensating patient. A few more minutes with the person in front of you instead of the screen.

AR
Arnaud Rosier, MD, PhDElectrophysiologist, CEO & Co-founder, Implicity

FAQ

Questions clinics ask us most.

What is the Implicity ILR ECG Analyzer†?

An FDA-cleared Class II software medical device† that reviews the ECG episodes implantable loop recorders (ICMs) send after the manufacturer’s own filtering. It suggests which ones are likely false positives, so clinicians can focus on clinically meaningful events.

Does it replace clinician review?

No. Results are advisory only. Every suggestion goes to a qualified healthcare professional, who accepts or changes it alongside their own clinical knowledge and other diagnostic information.†

Which loop recorders does it work with?

It is cleared for ICM ECG data from the following major manufacturers: Abbott, Biotronik, Boston Scientific and Medtronic.†

My ICMs already use AI. Why would I still see false positives?

Device filtering has improved, but a large share of the episodes that get through are still non-actionable. Pauses caused by R-wave undersensing are a common example.3 The ILR ECG Analyzer† works as a second layer on exactly those residual alerts.

When can my clinic use the next-generation algorithm?

Request a demo and we’ll walk you through the timing for your program.

Less noise · More patient ·
Less noise · More patient ·
Trust the signal ·
Trust the signal ·

See what your ILR queue looks like with a second layer of review.

Explore the platform
  1. †IM007 ILR ECG Analyzer is an FDA-cleared Class II medical device (Manufacturer: Implicity), intended for qualified healthcare professionals for assessment of arrhythmias in implantable cardiac monitor (ICM) ECG data from the following major manufacturers: Abbott, Biotronik, Boston Scientific and Medtronic. It operates as a second-layer analysis of residual alerts remaining after manufacturer filtering. The next-generation algorithm received FDA 510(k) clearance in July 2026 and is now commercially available to U.S. customers. Not for use in life-supporting or sustaining systems or ECG monitor and alarm devices. Results are advisory only, in conjunction with physician knowledge and other diagnostic information. See the instructions for use for more information.
  2. 1Varma N, Wadhwa M, Lazarus A, Faedda G, Mabo P, Crespin E. Performance of a cloud-based AI solution for reducing false positive alerts in implantable cardiac monitors detected episodes. Europace. 2026;28(Suppl 1):euag105.043.
  3. 2Marijon E, Crespin E, Leclercq C, Faedda G, Mabo P, Barraud J, Varma N. PO-01-235: Performance of a new cloud-based AI solution reducing false positive alerts in implantable cardiac monitor episodes on top of manufacturer AI algorithms. Heart Rhythm. 2026;23(4 Suppl):S294-S295.
  4. 3Implicity-sponsored analysis presented at EHRA 2026: 2,659 ICM episodes from 1,710 patients with Medtronic, Biotronik, Abbott and Boston Scientific devices, adjudicated by an independent expert committee using a guideline-aligned annotation framework. Presented at EHRA 2026, Paris, France, 12–14 April 2026.

The Implicity platform is a clinical decision support device and is in no way intended to replace the responsibility or clinical judgment of the practitioner. It is designed to optimize data workflows and support medical expertise in patient management.